Related references
Note: Only part of the references are listed.Impact of uPA System Gene Polymorphisms on the Susceptibility of Environmental Factors to Carcinogenesis and the Development of Clinicopathology of Oral Cancer
Chia-Jui Weng et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Association of polymorphisms in the genes of the urokinase plasminogen activation system with susceptibility to and severity of non-small cell lung cancer
Chuen-Ming Shih et al.
CLINICA CHIMICA ACTA (2011)
Genetic Polymorphism of the Plasminogen Activator Inhibitor-1 is Associated With an Increased Risk of Endometrial Cancer
Chung-Kuang Su et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Evaluation of the Association of Urokinase Plasminogen Activator System Gene Polymorphisms with Susceptibility and Pathological Development of Hepatocellular Carcinoma
Chia-Jui Weng et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Modulators of the urokinase-type plasminogen activation system for cancer
Ralf Hildenbrand et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Significant association of genetic polymorphism of human nonmetastatic clone 23 type 1 gene with an increased risk of endometrial cancer
Po-Hui Wang et al.
GYNECOLOGIC ONCOLOGY (2010)
Effectiveness of national cervical cancer screening programme in Taiwan: 12-year experiences
Y-Y Chen et al.
BRITISH JOURNAL OF CANCER (2009)
Effects of nonsteroidal anti-inflammatory drugs on the expression of urokinase plasminogen activator and inhibitor and gelatinases in the early osteoarthritic knee of humans
Shun-Fa Yang et al.
CLINICAL BIOCHEMISTRY (2008)
Diagnosis and management of cervical cancer
Patrick Petignat et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
A significant elevation of plasma level of matrix metalloproteinase-9 in patients with high-grade intraepithelial neoplasia and early squamous cell carcinoma of the uterine cervix
Shun-Fa Yang et al.
REPRODUCTIVE SCIENCES (2007)
Plasminogen activator inhibitor type-I (PAI-I) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history
Eric Jorgenson et al.
PROSTATE (2007)
Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity
R Castello et al.
THROMBOSIS RESEARCH (2006)
The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
MJ Duffy et al.
CLINICAL BIOCHEMISTRY (2004)
The urokinase plasminogen activator system: Role in malignancy
MJ Duffy
CURRENT PHARMACEUTICAL DESIGN (2004)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
MP Look et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
MS Pepper
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2001)
Share Paper
